Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 4, 2011, Pages

  Ravassa, Susana ^a   Zudaire, Amaia ^a   Carr, Richard D ^b   Díez, Javier ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b MSD A/S   (Denmark)

Author keywords

Apoptosis; Cardiomyocytes; Glucagon like peptide 1; Reperfusion injury salvage kinase pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; CERAMIDE; CYTOCHROME C; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PALMITIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BNIP3; SERINE DERIVATIVE; STAUROSPORINE; THREONINE; WORTMANNIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME RELEASE; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE; CERAMIDES; CYTOCHROMES C; DNA FRAGMENTATION; ENZYME INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INCRETINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MICE; MITOCHONDRIAL PROTEINS; MYOCYTES, CARDIAC; PALMITATES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLSERINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STAUROSPORINE; TOR SERINE-THREONINE KINASES;

EID: 79955067267     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00885.2010     Document Type: Article

References (50)

1. Achenbach TV, Müller R, Slater EP. Bcl-2 independence of flavopiri-dol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 275: 32089-32097, 2000.
2. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Green-stein A, Heagerty AM, Malik RA. Diabetic cardiomyopathy. Clin Sci 116: 741-760, 2009.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastro-enterology 132: 2131-2157, 2007.
4. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350, 2008.
5. Baraka A, AbdelGawad H. Targeting apoptosis in the heart of strepto-zotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther 15: 175-181, 2010.
6. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cyto-kines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 41: 35-44, 2008.
7. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
8. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19: 9-11, 2005.
9. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 21: 253-256, 2007.
10. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-22, 2001.
11. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyo-cyte. Proc Natl Acad Sci USA 95: 2979-2984, 1998.
12. Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL, Cnop M. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58: 2851-2862, 2009.
13. Dorn GW. Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors. J Cardiovasc Transl Res 3: 374-83, 2010.
14. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 277: 48146-48151, 2002.
15. González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacar-rillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126: 203-211, 2005.
16. Hargrove DM, Nardone NA, Persson LM, Andrews KM, Shepherd KL, Stevenson RW, Parker JC. Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo. Metabolism 45: 404-409, 1996.
17. Hickson-Bick DL, Buja LM, McMillin JB. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32: 511-519, 2000.
18. Holz GG. New insights concerning the glucose-dependent insulin secre-tagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res 36: 787-794, 2004.
19. Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 19: 77-83, 2008.
20. Johnson BW, Cepero E, Boise LH. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. J Biol Chem 275: 31546-31553, 2000.
21. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132, 2008.
22. Katare RG, Caporali A, Oikawa A, Meloni M, Emanueli C, Madeddu P. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail 3: 294-305, 2010.
23. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, Joh T. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell ap-optosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 162: 1212-1219, 2009.
24. Kuethe F, Sigusch HH, Bornstein SR, Hilbig K, Kamvissi V, Figulla HR. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy? Horm Metab Res 39: 672-676, 2007.
25. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 14: 536-548, 2009.
26. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003.
27. Liu JH, Yin F, Guo LX, Deng XH, Hu YH. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 30: 159-165, 2009.
28. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG. Glucagon-like peptide-1 and the exenatide analog AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure (Abstract). Cardiovasc Diabetol 9: 76, 2010.
29. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Benedetti A. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 58: 990-997, 2009.
30. Nakagawa M, Tsujimoto N, Nakagawa H, Iwaki T, Fukumaki Y, Iwaki A. Association of HSPB2, a member of the small heat shock protein family, with mitochondria. Exp Cell Res 271: 161-168, 2001.
31. Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M. Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin 19: 113-126, 2001.
32. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, Dal Bello B, Semigran MJ, Bielsa-Masdeu A, Dec GW, Israels S, Ballester M, Virmani R, Saxena S, Kharbanda S. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 96: 8144-8149, 1999.
33. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993.
34. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84-90, 2009.
35. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52, 1986.
36. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zoure-lias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardio-myopathy. Circulation 110: 955-961, 2004.
37. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983, 2009.
38. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160, 2008.
39. Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett 444: 217-221, 2008.
40. Quinsay MN, Lee Y, Rikka S, Sayen MR, Molkentin JD, Gottlieb RA, Gustafsson AB. Bnip3 mediates permeabilization of mitochondria and release of cytochrome c via a novel mechanism. J Mol Cell Cardiol 48: 1146-1156, 2010.
41. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G, Dalle S. GLP-1 mediates antiapoptotic effect by phos-phorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285: 1989-2002, 2010.
42. Ravassa S, García-Bolao I, Zudaire A, Macías A, Gavira JJ, Beaumont J, Arias T, Huerta A, Díez J. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res 88: 304-313, 2010.
43. Reed JC, Paternostro G. Postmitochondrial regulation of apoptosis during heart failure. Proc Natl Acad Sci USA 96: 7614-7616, 1999.
44. Sancho V, Nuche B, Arnés L, Cancelas J, González N, Díaz-Miguel M, Martín-Duce A, Valverde I, Villanueva-Peñacarrillo ML. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int J Mol Med 19: 961-966, 2007.
45. Tews D, Lehr S, Hartwig S, Osmers A, Paslack W, Eckel J. Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res 41: 294-301, 2009.
46. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510, 2009.
47. Wei H, L'Ecuyer T, vander Heide RS. Effect of increased expression of cytoskeletal protein vinculin on ischemia-reperfusion injury in ventricular myocytes. Am J Physiol Heart Circ Physiol 284: H911-H918, 2003.
48. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 286: H823-H829, 2004.
49. Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP, Li DQ, Yu DM. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J 121: 2134-2138, 2008.
50. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113, 2006.